External radiotherapy combined with sorafenib has better efficacy in unresectable hepatocellular carcinoma: a systematic review and meta-analysis

Li, Han; Wu, Zhenying; Chen, Jiali; Su, Ke; Guo, Lu; Xu, Ke; Gu, Tao; Jiang, Yi; Wang, Pan; Zeng, Hao; Chi, Hao; He, Kun; Han, Yunwei

doi:10.1007/s10238-022-00972-4

Cited by 27 publications

(19 citation statements)

References 87 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Some studies have shown that the combination of TACE, external radiotherapy, internal radiotherapy and sorafenib or lenvatinib has an positive clinical effect. 4,21,[24][25][26] Su and others demonstrated that radiotherapy combined with PD-1 and targeted therapy has survival benefits, 27 further proving the bright prospect of TACE combined with target immunotherapy.…”

Section: Discussionmentioning

confidence: 98%

“…TACE can upregulate tumor antigens and "danger" signals, which can make the tumor more responsive to immunotherapy. 20,21 At present, the development of TACE has shown an increasing trend. Studies have shown that stable homogeneous iodide preparation technology (SHIFT) can fully disperse ICG (indocyanine green) into lipid iodine for transcatheter embolization combined with fluorescence guided resection.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

PD-1 Inhibitors Combined with Antiangiogenic Therapy with or Without Transarterial Chemoembolization in the Treatment of Hepatocellular Carcinoma: A Propensity Matching Analysis

Han¹,

Su²,

Guo³

et al. 2023

JHC

Self Cite

View full text Add to dashboard Cite

Background: At present, it is not known whether targeting plus immunotherapy combined with transarterial chemoembolization (TACE) can improve the efficacy of hepatocellular carcinoma (HCC). The aim of this retrospective experiment was to explore the difference in clinical efficacy between antiangiogenic drugs plus PD-1 inhibitors combined with and without TACE. Methods: Clinical data of 145 patients with HCC who received anti-angiogenesis therapy plus PD-1 inhibitor combined with TACE (TACE-P-T) (n = 62) or anti-angiogenesis therapy combined with PD-1 inhibitor (P-T) (n = 83) in China from October 2018 to December 2022 were collected and reviewed. We used propensity matching (PSM) to create two groups with comparable baseline scores, compared their median survival time (mOS) and median progression-free survival time (mPFS), and performed subgroup analysis. Results: Before PSM, the mOS and mPFS of patients were 20.3 and 5.0 months in the triple therapy group and 13.6 and 7.4 months in the control group, respectively. After PSM, the mOS and mPFS of patients were 19.7 and 6.6 months in the triple treatment group and 10.5 and 3.7 months in the control group, respectively. Therefore, the TACE-P-T group showed better survival outcomes than P-T. In the subgroup analysis, compared with the control group, the mOS was 10.7 vs 20.3 months in the alpha fetoprotein (AFP) (≥ 400ng/mL/<400ng/mL) group, 29.3 vs 7.4 months in the alkaline phosphatase (ALP) (≥ 125u/L/< 125u/L) group and 10.5 vs 20.0 months in the Portal vein invasion (PVTT) group. Conclusion: Antiangiogenic therapy combined with PD-1 inhibitors combined with TACE has significant survival benefits for HCC patients.

show abstract

Section: Discussionmentioning

confidence: 98%

Section: Discussionmentioning

confidence: 99%

PD-1 Inhibitors Combined with Antiangiogenic Therapy with or Without Transarterial Chemoembolization in the Treatment of Hepatocellular Carcinoma: A Propensity Matching Analysis

Han¹,

Su²,

Guo³

et al. 2023

JHC

Self Cite

View full text Add to dashboard Cite

show abstract

“…This proposed BBB model could act as a future backbone for evaluating the efficacy of treatments for glioma and the passage of drug cargos through the BBB for testing cutting-edge glioma theranostics. Treatment of gliomas has long been a major challenge of neuro-oncology due to the tumor heterogeneity and the diffuse and infiltrative nature of the growth of the high-grade gliomas and hence much attempt has been devoted to improving the efficacy of glioma treatment comprising using external beam radiation or external beam radiation and soferanib ( 52 , 53 ). This proposed BBB model could aid in improving translational research on the impact of external beam radiation or other chemotherapies for glioma treatment in the future.…”

Section: Discussionmentioning

confidence: 99%

A dynamic study of VEGF-A siDOX-EVs trafficking through the in-vitro insert co-culture blood-brain barrier model by digital holographic microscopy

Shamshiripour,

Rahnama,

Nikoobakht

et al. 2024

Front. Oncol.

View full text Add to dashboard Cite

IntroductionModeling the blood-brain barrier has long been a challenge for pharmacological studies. Up to the present, numerous attempts have been devoted to recapitulating the endothelial barrier in vitro to assess drug delivery vehicles’ efficiency for brain disorders. In the current work, we presented a new approach for analyzing the morphometric parameters of the cells of an insert co-culture blood-brain barrier model using rat brain astrocytes, rat brain microvascular endothelial cells, and rat brain pericytes. This analytical approach could aid in getting further information on drug trafficking through the blood-brain barrier and its impact on the brain indirectly.MethodsIn the current work, we cultured rat brain astrocytes, rat brain microvascular endothelial cells, and rat brain pericytes and then used an insert well to culture the cells in contact with each other to model the blood-brain barrier. Then, the morphometric parameters of the porous membrane of the insert well, as well as each cell type were imaged by digital holographic microscopy before and after cell seeding. At last, we performed folate conjugation on the surface of the EVs we have previously tested for glioma therapy in our previous work called VEGF-A siDOX-EVs and checked how the trafficking of EVs improves after folate conjugation as a clathrin-mediated delivery setup. the trafficking and passage of EVs were assessed by flow cytometry and morphometric analysis of the digital holographic microscopy holograms.ResultsOur results indicated that EVs successfully entered through the proposed endothelial barrier assessed by flow cytometry analysis and furthermore, folate conjugation significantly improved EV passage through the blood-brain barrier. Moreover, our results indicated that the VEGF-A siDOX-EVs insert cytotoxic impact on the cells of the bottom of the culture plate.Conclusionfolate-conjugation on the surface of EVs improves their trafficking through the blood-brain barrier and by using digital holographic microscopy analysis, we could directly assess the morphometric changes of the blood-brain barrier cells for pharmacological purposes as an easy, label-free, and real-time analysis.

show abstract

“…In China, HCC is the second leading cause of cancer-related deaths ( 4 ). The development of HCC is a multistage and multifactorial process, and HCC is heterogeneous and characterized by high tumor invasiveness, frequent recurrence, and poor prognosis ( 5 ). Some serum biomarkers were used in the early diagnosis and prognosis of HCC ( 6 , 7 ).…”

Section: Introductionmentioning

confidence: 99%

A radiomics nomogram for predicting cytokeratin 19–positive hepatocellular carcinoma: a two-center study

et al. 2023

View full text Add to dashboard Cite

ObjectivesWe aimed to construct and validate a radiomics-based nomogram model derived from gadoxetic acid–enhanced magnetic resonance (MR) images to predict cytokeratin (CK) 19–positive (+) hepatocellular carcinoma (HCC) and patients’ prognosis.MethodsA two-center and time-independent cohort of 311 patients were retrospectively enrolled (training cohort, n = 168; internal validation cohort, n = 72; external validation cohort, n = 71). A total of 2286 radiomic features were extracted from multisequence MR images with the uAI Research Portal (uRP), and a radiomic feature model was established. A combined model was established by incorporating the clinic-radiological features and the fusion radiomics signature using logistic regression analysis. Receiver operating characteristic curve (ROC) was used to evaluate the predictive efficacy of these models. Kaplan–Meier survival analysis was used to assess 1-year and 2-year progression-free survival (PFS) and overall survival (OS) in the cohort.ResultsBy combining radiomic features extracted in DWI phase, arterial phase, venous and delay phase, the fusion radiomics signature achieved AUCs of 0.865, 0.824, and 0.781 in the training, internal, and external validation cohorts. The final combined clinic-radiological model showed higher AUC values in the three datasets compared with the fusion radiomics model. The nomogram based on the combined model showed satisfactory prediction performance in the training (C-index, 0.914), internal (C-index, 0.855), and external validation (C-index, 0.795) cohort. The 1-year and 2-year PFS and OS of the patients in the CK19+ group were 76% and 73%, and 78% and 68%, respectively. The 1-year and 2-year PFS and OS of the patients in the CK19-negative (−) group were 81% and 77%, and 80% and 74%, respectively. Kaplan–Meier survival analysis showed no significant differences in 1-year PFS and OS between the groups (P = 0.273 and 0.290), but it did show differences in 2-year PFS and OS between the groups (P = 0.032 and 0.040). Both PFS and OS were lower in CK19+ patients.ConclusionThe combined model based on clinic-radiological radiomics features can be used for predicting CK19+ HCC noninvasively to assist in the development of personalized treatment.

show abstract

External radiotherapy combined with sorafenib has better efficacy in unresectable hepatocellular carcinoma: a systematic review and meta-analysis

Cited by 27 publications

References 87 publications

PD-1 Inhibitors Combined with Antiangiogenic Therapy with or Without Transarterial Chemoembolization in the Treatment of Hepatocellular Carcinoma: A Propensity Matching Analysis

PD-1 Inhibitors Combined with Antiangiogenic Therapy with or Without Transarterial Chemoembolization in the Treatment of Hepatocellular Carcinoma: A Propensity Matching Analysis

A dynamic study of VEGF-A siDOX-EVs trafficking through the in-vitro insert co-culture blood-brain barrier model by digital holographic microscopy

A radiomics nomogram for predicting cytokeratin 19–positive hepatocellular carcinoma: a two-center study

Contact Info

Product

Resources

About